{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:20:41Z","timestamp":1790036441933,"version":"4.0.1"},"reference-count":6,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T00:00:00Z","timestamp":1528243200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Nephrol"],"published-print":{"date-parts":[[2018,8]]},"DOI":"10.1038\/s41581-018-0028-0","type":"journal-article","created":{"date-parts":[[2018,6,6]],"date-time":"2018-06-06T11:06:35Z","timestamp":1528283195000},"page":"473-474","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":69,"title":["Adverse effects of SGLT2 inhibitors on bone health"],"prefix":"10.1038","volume":"14","author":[{"given":"Jenny E.","family":"Blau","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simeon I.","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,6]]},"reference":[{"key":"28_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrneph.2016.170","volume":"13","author":"RA DeFronzo","year":"2017","unstructured":"DeFronzo, R. A., Norton, L. & Abdul-Ghani, M. Renal, metabolic and cardiovascular considerations of SGLT2 inhibition. Nat. Rev. Nephrol. 13, 11\u201326 (2017).","journal-title":"Nat. Rev. Nephrol."},{"key":"28_CR2","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1038\/ki.2013.356","volume":"85","author":"DE Kohan","year":"2014","unstructured":"Kohan, D. E., Fioretto, P., Tang, W. & List, J. F. Long-term study of patients with type 2 diabetes and moderate renal impairment shows that dapagliflozin reduces weight and blood pressure but does not improve glycemic control. Kidney Int. 85, 962\u2013971 (2014).","journal-title":"Kidney Int."},{"key":"28_CR3","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1210\/jc.2015-1860","volume":"101","author":"JP Bilezikian","year":"2016","unstructured":"Bilezikian, J. P. et al. Evaluation of bone mineral density and bone biomarkers in patients with type 2 diabetes treated with canagliflozin. J. Clin. Endocrinol. Metab. 101, 44\u201351 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"28_CR4","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1210\/jc.2015-3167","volume":"101","author":"NB Watts","year":"2016","unstructured":"Watts, N. B. et al. Effects of canagliflozin on fracture risk in patients with type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 101, 157\u2013166 (2016).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"28_CR5","doi-asserted-by":"publisher","first-page":"99123","DOI":"10.1172\/jci.insight.99123","volume":"3","author":"JE Blau","year":"2018","unstructured":"Blau, J. E. et al. Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study. JCI Insight 3, 99123 (2018).","journal-title":"JCI Insight"},{"key":"28_CR6","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1152\/ajplegacy.1944.142.5.648","volume":"142","author":"RF Pitts","year":"1944","unstructured":"Pitts, R. F. & Alexander, R. S. The renal reabsorptive mechanism for inorganic phosphate in normal and acidotic dogs. Am. J. Physiol. 142, 648\u2013662 (1944).","journal-title":"Am. J. Physiol."}],"container-title":["Nature Reviews Nephrology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0028-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0028-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41581-018-0028-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T22:07:27Z","timestamp":1684620447000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41581-018-0028-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,6]]},"references-count":6,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["28"],"URL":"https:\/\/doi.org\/10.1038\/s41581-018-0028-0","relation":{},"ISSN":["1759-5061","1759-507X"],"issn-type":[{"value":"1759-5061","type":"print"},{"value":"1759-507X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,6]]},"assertion":[{"value":"6 June 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J.E.B. declares no competing interests. S.I.T. is a consultant for Ionis Pharmaceuticals, has research support provided to the University of Maryland School of Medicine by Regeneron Pharmaceuticals and has ownership of stock in Celgene, Amgen and Abbott Laboratories.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}